Imricor Plans Major CDI Placement to Raise Capital on ASX

Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh ( (AU:IMR) ) has provided an announcement.

Imricor Medical Systems has notified the ASX of a proposed placement involving the issue of up to 32,432,433 CHESS Depositary Interests, each representing one share, under the code IMR CDI 1:1 US PERSON PROHIBITED EXCLUDING QIB. The new securities are scheduled for issue on 8 May 2026, signalling a capital-raising move that may strengthen the company’s funding position and support its ongoing operational and growth initiatives.

The placement structure indicates Imricor is targeting non-U.S. investors, with exclusions for certain U.S. persons except qualified institutional buyers, aligning the offer with cross-border securities regulations. This proposed issuance could expand the company’s shareholder base on the ASX and provide additional resources for executing its strategic plans in the medical technology market.

The most recent analyst rating on (AU:IMR) stock is a Buy with a A$2.63 price target. To see the full list of analyst forecasts on Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:IMR Stock Forecast page.

More about Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh

Imricor Medical Systems, Inc. is a medical technology company listed on the ASX under the code IMR. It focuses on developing and commercialising cardiac-related medical systems and solutions, with its securities traded via CHESS Depositary Interests, giving investors exposure to its U.S.-based operations.

Average Trading Volume: 323,908

Technical Sentiment Signal: Buy

Current Market Cap: A$633.9M

For detailed information about IMR stock, go to TipRanks’ Stock Analysis page.